Overview
NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B. This is because Gilead did not provide an evidence submission.
Last reviewed: 22 March 2017
Next review: We will review this decision if the company decides to make a submission.